Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2017
This article has no abstract
Epistemonikos ID: afbfb4e9bbd1e96619eebb029de060b25757a54e
First added on: Feb 08, 2025